Comunicación corta
Rituximab en queratitis ulcerativa periférica asociada a artritis reumatoide
Rituximab in rheumatoid arthritis-associated peripheral ulcerative keratitis
Leído
4728
Vecesse ha leído el artículo
1292
Total PDF
3436
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 6 | 6 |
| 2025 11 | 0 | 19 | 19 |
| 2025 10 | 0 | 15 | 15 |
| 2025 9 | 0 | 9 | 9 |
| 2025 8 | 0 | 6 | 6 |
| 2025 7 | 0 | 2 | 2 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 4 | 4 |
| 2025 4 | 0 | 1 | 1 |
| 2025 3 | 0 | 3 | 3 |
| 2025 2 | 0 | 2 | 2 |
| 2025 1 | 0 | 2 | 2 |
| 2024 12 | 1 | 2 | 3 |
| 2024 11 | 0 | 2 | 2 |
| 2024 10 | 0 | 3 | 3 |
| 2024 9 | 0 | 5 | 5 |
| 2024 8 | 1 | 7 | 8 |
| 2024 7 | 0 | 1 | 1 |
| 2024 6 | 0 | 5 | 5 |
| 2024 5 | 0 | 5 | 5 |
| 2024 4 | 0 | 9 | 9 |
| 2024 3 | 0 | 14 | 14 |
| 2024 2 | 0 | 5 | 5 |
| 2024 1 | 0 | 3 | 3 |
| 2023 12 | 0 | 10 | 10 |
| 2023 11 | 0 | 6 | 6 |
| 2023 10 | 0 | 15 | 15 |
| 2023 9 | 0 | 5 | 5 |
| 2023 8 | 0 | 4 | 4 |
| 2023 7 | 0 | 13 | 13 |
| 2023 6 | 0 | 9 | 9 |
| 2023 5 | 0 | 7 | 7 |
| 2023 4 | 0 | 1 | 1 |
| 2023 3 | 1 | 11 | 12 |
| 2023 2 | 0 | 8 | 8 |
| 2022 1 | 0 | 7 | 7 |
| 2022 12 | 0 | 3 | 3 |
| 2022 11 | 0 | 11 | 11 |
| 2022 10 | 0 | 6 | 6 |
| 2022 9 | 0 | 28 | 28 |
| 2022 8 | 0 | 9 | 9 |
| 2022 7 | 0 | 2 | 2 |
| 2022 6 | 0 | 12 | 12 |
| 2022 5 | 0 | 5 | 5 |
| 2022 4 | 0 | 3 | 3 |
| 2021 1 | 0 | 3 | 3 |
| 2021 12 | 0 | 5 | 5 |
| 2021 11 | 0 | 5 | 5 |
| 2021 10 | 0 | 1 | 1 |
| 2021 9 | 0 | 1 | 1 |
| 2021 8 | 0 | 4 | 4 |
| 2021 7 | 0 | 4 | 4 |
| 2021 6 | 0 | 3 | 3 |
| 2021 5 | 0 | 2 | 2 |
| 2021 4 | 0 | 24 | 24 |
| 2021 3 | 0 | 1 | 1 |
| 2021 2 | 0 | 3 | 3 |
| 2020 1 | 0 | 5 | 5 |
| 2020 12 | 0 | 2 | 2 |
| 2020 11 | 0 | 4 | 4 |
| 2020 10 | 0 | 5 | 5 |
| 2020 9 | 0 | 2 | 2 |
| 2020 8 | 0 | 5 | 5 |
| 2020 7 | 0 | 2 | 2 |
| 2020 6 | 1 | 4 | 5 |
| 2020 5 | 0 | 2 | 2 |
| 2020 4 | 0 | 3 | 3 |
| 2020 3 | 0 | 3 | 3 |
| 2020 2 | 0 | 1 | 1 |
| 2020 1 | 0 | 8 | 8 |
| 2019 12 | 0 | 13 | 13 |
| 2019 11 | 0 | 2 | 2 |
| 2019 10 | 0 | 2 | 2 |
| 2019 8 | 0 | 2 | 2 |
| 2019 7 | 0 | 5 | 5 |
| 2019 6 | 0 | 4 | 4 |
| 2019 5 | 0 | 35 | 35 |
| 2019 4 | 0 | 13 | 13 |
| 2019 3 | 0 | 4 | 4 |
| 2019 2 | 0 | 6 | 6 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 3 | 3 |
| 2018 11 | 0 | 6 | 6 |
| 2018 10 | 0 | 14 | 14 |
| 2018 2 | 17 | 2 | 19 |
| 2018 1 | 17 | 6 | 23 |
| 2017 12 | 13 | 3 | 16 |
| 2017 11 | 23 | 3 | 26 |
| 2017 10 | 15 | 6 | 21 |
| 2017 9 | 14 | 10 | 24 |
| 2017 8 | 24 | 14 | 38 |
| 2017 7 | 13 | 8 | 21 |
| 2017 6 | 11 | 8 | 19 |
| 2017 5 | 32 | 14 | 46 |
| 2017 4 | 17 | 10 | 27 |
| 2017 3 | 28 | 21 | 49 |
| 2017 2 | 23 | 12 | 35 |
| 2016 1 | 23 | 6 | 29 |
| 2016 12 | 41 | 22 | 63 |
| 2016 11 | 53 | 20 | 73 |
| 2016 10 | 42 | 21 | 63 |
| 2016 9 | 74 | 14 | 88 |
| 2016 8 | 66 | 19 | 85 |
| 2016 7 | 43 | 2 | 45 |
| 2016 6 | 43 | 24 | 67 |
| 2016 5 | 36 | 35 | 71 |
| 2016 4 | 50 | 25 | 75 |
| 2016 3 | 38 | 28 | 66 |
| 2016 2 | 31 | 25 | 56 |
| 2015 1 | 33 | 21 | 54 |
| 2015 12 | 28 | 24 | 52 |
| 2015 11 | 30 | 27 | 57 |
| 2015 10 | 31 | 22 | 53 |
| 2015 9 | 33 | 21 | 54 |
| 2015 8 | 47 | 14 | 61 |
| 2015 7 | 43 | 10 | 53 |
| 2015 6 | 22 | 5 | 27 |
| 2015 5 | 40 | 13 | 53 |
| 2015 4 | 40 | 15 | 55 |
| 2015 3 | 45 | 15 | 60 |
| 2015 2 | 39 | 5 | 44 |
| 2015 1 | 51 | 10 | 61 |
| 2014 12 | 58 | 26 | 84 |
| 2014 11 | 53 | 11 | 64 |
| 2014 10 | 69 | 19 | 88 |
| 2014 9 | 63 | 18 | 81 |
| 2014 8 | 57 | 15 | 72 |
| 2014 7 | 61 | 10 | 71 |
| 2014 6 | 53 | 10 | 63 |
| 2014 5 | 33 | 13 | 46 |
| 2014 4 | 48 | 21 | 69 |
| 2014 3 | 34 | 13 | 47 |
| 2014 2 | 40 | 13 | 53 |
| 2014 1 | 41 | 6 | 47 |
| 2013 12 | 51 | 8 | 59 |
| 2013 11 | 42 | 7 | 49 |
| 2013 10 | 32 | 8 | 40 |
| 2013 9 | 61 | 7 | 68 |
| 2013 8 | 15 | 4 | 19 |
| 2013 7 | 11 | 4 | 15 |
| 2011 3 | 1341 | 0 | 1341 |
Mostrar todo
